At Abcam, we take pride in building teams that collaborate effectively, designing environments that help people perform at their best. A key part of this is listening to our employees to create spaces that work for them, alongside areas that foster collaborative, in-person connections 🙌 Hannah Tweddle, Manufacturing Data Lead, experiences these benefits first-hand: “When I see how much people enjoy working together, I know this place is for me.” If this sounds like the kind of work environment you’d thrive in, we’d love to hear from you. Click the link to learn more about joining Abcam and view our current vacancies:

Reach your next breakthrough with tailored solutions designed to overcome the unique challenges of obesity drug discovery. Learn more about our solutions for obesity research here 👉

Among other discoveries, American microbiologist Esther Lederberg revolutionized the field of microbial genetics by discovering the lambda phage in the early 1950s – a bacterial virus that became a widely used tool for studying genetic recombination and gene regulation. Her work paved the way for medical and biotechnology breakthroughs and advanced our understanding of genetic variation and evolution. Lederberg's innovative methods continue to shape the field of life sciences today. At Abcam, we believe that breakthroughs made by one of us empower us all. #progresshappenstogether

With our new 20 µl trial sizes for over 3,000 recombinant antibodies, you can easily test your antibody or perform pre-screening before committing to a larger quantity. Have confidence in consistent results and move your research forward – learn more here:

Our portfolio includes antibodies to 90% of key targets in major glioblastoma pathways, including mTOR. See our pathway poster to learn how mTOR regulates cellular processes. Download here:

This week on #BehindtheBreakthroughs, we’re going back to our bread and butter: the antibody. The antibody’s Y-shaped structure was discovered by Rodney Porter and Gerald Edelman in the late 50s and early 60s, providing fundamental insight into the body's immune response. Their theory revolutionized our understanding of how the immune system generates a range of antibodies to combat different diseases, leading to advancements in immunology, vaccine development, and antibody-based therapies, saving many lives. #Progresshappenstogethern

Attending #SLAS2025? Join our #immunoassay experts for lunch at 12pm, room 28B and learn how SimpleStep ELISA® technology and SureFire® assays can enhance research efficiency and precision 🧪🌟

Set your week up for success with one of our top pathways. The tumor microenvironment (TME) consists of various support cells subverted by the cancer cells to assist in the progression of the tumor. Here we review the complex interplay of the tumor, stromal cells, and immune cells within the TME. Download your copy of our tumor microenvironment pathway:

Excited to be at #SLAS2025! Visit us at @‌DanaherCorp booth #1619 to catch a demo of our 384-well ELISA on a @‌BCILifeSciences Biomek i5. Plus, join us for lunch on Jan 28 in room 28B and hear from our #immunoassay experts 🧪 🌟

Our SimpleStep ELISA® kits are designed to help you achieve more, faster. Powered by recombinant technology for reproducible results, these kits can take you from sample to result in just 90 minutes. Discover how our kits can drive your research forward, faster:

Barbara McClintock's observation that no two maize plants were alike led her to investigate, and later challenge, the prevailing genetic theory of the 1930s and 40s. Throughout her career in cytogenetics, Barbara made discovery after discovery. Today, much of our understanding of genetics, medicine, and evolutionary biology is based on her findings. At Abcam, we believe that breakthroughs made by one of us empower us all. #progresshappenstogether

At Abcam, we understand that sometimes, life can get in the way. That's why we adopt a culture of trust and respect for individual needs, demonstrated through flexibility and unique opportunities. Emily Dell, Service Enablement Lead, says: “I love how easily I can fit work around my life and personal priorities.” If this sounds like the work environment for you, get in touch! Visit our careers site today:

What gets you into the lab on a Monday morning? For Joe, it's to answer a fundamental question: what makes us human? Or in his words: “Trying to understand what makes you you, and what makes me me.” In our award nominated short film series ‘Love Letters to Science’, Joe tells us how he chose biology class at school when philosophy wasn’t giving him adequate answers. In this first class, he learned something that meant he would never turn back from science. Find out what it was in episode 3 of the series here:

🌟 Connect, learn, and share ideas with fellow #cancer and #metabolism researchers at #CancerandMetabolism in Austin TX and online next month! Whether you join us in person or virtually, you'll gain valuable insights and inspiration to drive your research forward 💡 #conference #oncology #progresshappenstogether

🚨 Just published 🚨 Together with collaborators at @mcgillu @theneuro_mni @YCharOS1, as well as other antibody manufacturers, we’re excited to announce the publication of a new open science platform for the characterization of research antibodies. The approach, published in @nature, aims to set out an industry standard for antibody characterization that will enable researchers to effectively compare performance of antibodies in various applications, and ultimately support enhanced reliability and reproducibility of scientific research. Discover more about the news here: Read the paper here:

Kickstart your year with insights into #innateimmunity and #inflammasome biology! Register for the #InflammaZoom, our free monthly webinar series. Next session: January 20 at 8.00am GMT w/ @keshu_VRimmCh -@iiscbangalore & @mere_conjecture - @UTAS_

With our new 20 µl trial size antibodies you can experience the specificity and reproducibility of recombinant antibodies without the risk. Look for the 20 µl tag on our product search results and move to the next step with confidence:

We’re excited to announce that Nadia Altomare has joined Abcam as our new Vice President of Commercial Operations. With over 20 years of experience in the biotech, diagnostics, and life sciences industries combined, Nadia brings a wealth of expertise, fresh perspectives, and innovative ideas to our team. We're excited about the impact she’ll have in driving Abcam’s commercial strategy and look forward to her contributions as we continue to empower scientific discoveries worldwide. Please join us in giving Nadia a warm welcome to the Abcam community! 🎉

@cy81yukawa 💙🧡

Research is challenging. We get it. There are highs and lows. Good days and bad days. But whatever you’re using our immunoassays for, we’re here to help you every step of the way. See how we can work together. Scale with confidence.